METHOD FOR PREDICTION OF EFFICACY OF INFLIXIMAB INCLUSION IN THERAPY OF PATIENTS WITH RHEUMATOID ARTHRITIS Russian patent published in 2011 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: invention concerns a method for prediction of the efficacy of Infliximab inclusion in a conventional therapy of the patients with rheumatoid arthritis (RA). A patient's peripheral blood is examined for total lymphocyte content (TLC) expressing TNF-α-CD120a receptors, for levels of spontaneous and stimulated production of tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6). It is followed by calculating indexes of PHA action on PBMC (peripheral blood mononuclear cells) TNF-α and IL-6 production by formulae respectively: IA₁=A_st/A_sp, IA₂=B_st/B_sp, where IA₁ is an index of PHA action on PBMC TNF-α production; A_st is a level of stimulated TNF-α production, pg/ml; A_sp is a level of spontaneous TNF-α production, pg/ml; IA₂ is an index of PHA action on PBMC IL-6 production; B_st is a level of stimulated IL-6 production, pg/ml; B_sp is a level of spontaneous IL-6 production, pg/ml. Provided IA₁≤2.4 and IA₂≤1.6 and TLC≥6% simultaneously, the high efficacy of Infliximab inclusion in the therapy of the RA patients is predicted.

EFFECT: invention allows reliable prediction of the efficacy of Infliximab inclusion in the conventional therapy of the RA patients.

1 ex